Every 10-Q that Allogene Therapeutics, Inc. (ALLO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLO filings page.
Allogene Therapeutics, Inc. reported a Q2 2026 net loss of $42.7 million, improved from $50.9 million a year earlier, on collaboration revenue of $4.6 million from terminating its Overland Therapeutics license. Operating expenses fell to $51.6 million from $56.8 million, driven mainly by lower research and development spending.
Cash, cash equivalents and investments totaled $423.6 million as of June 30, 2026, supported by a $187.9 million April 2026 public equity offering and $20.7 million raised via at-the-market sales. The company expects this liquidity to fund operations into the first quarter of 2029, while still acknowledging the need for additional capital to fully execute its plans.
Allogene continues to focus on three core programs: the pivotal ALPHA3 trial of cema‑cel in first‑line large B‑cell lymphoma, the TRAVERSE Phase 1b trial of ALLO‑316 in renal cell carcinoma, and the RESOLUTION Phase 1 autoimmune basket study of ALLO‑329 using its Dagger® platform to potentially reduce or eliminate standard lymphodepletion.
Allogene Therapeutics, Inc. reported a net loss of $42.6 million for the quarter ended March 31, 2026, improving from $59.7 million a year earlier as total operating expenses fell to $46.1 million from $65.2 million.
Cash, cash equivalents and investments totaled $266.9 million at quarter‑end, before an additional $187.9 million in net proceeds from an April 2026 equity offering of 100.2 million shares at $2.00 per share. The company now expects its cash resources to fund operations into the first quarter of 2029.
Allogene continues to focus on three core programs: the pivotal ALPHA3 trial of cema‑cel in first‑line large B‑cell lymphoma, the TRAVERSE study of ALLO‑316 in renal cell carcinoma, and the RESOLUTION basket trial of ALLO‑329 in autoimmune diseases, all supported by its Dagger® platform and multiple external collaborations.
Allogene Therapeutics (ALLO) reported Q3 2025 results showing a narrower net loss of $41.4 million versus $66.3 million a year ago as operating expenses fell to $44.9 million from $71.8 million. Interest and other income contributed $3.5 million in the quarter.
Liquidity and runway: Cash, cash equivalents and investments were $277.1 million as of September 30, 2025, and management stated these resources are expected to fund operations for at least 12 months from the filing date. Net cash used in operating activities was $121.6 million for the nine months ended September 30, 2025.
Capital actions and structure: The company sold 7,477,047 shares via its ATM in the nine months ended September 30, 2025, generating $14.5 million in net proceeds. Shares issued and outstanding were 223,163,672 as of September 30, 2025; 224,730,144 were outstanding as of November 4, 2025.
Operations and costs: R&D expense was $31.2 million in Q3 (down from $44.7 million), and G&A was $13.7 million (down from $16.3 million). Year-to-date impairment of long-lived assets was $2.4 million, including effects related to subleased facilities. A workforce reduction approved in May 2025 (approximately 28%) resulted in $4.7 million of charges year-to-date.
Programs and funding: The company received $9.2 million to date under the CIRM award tied to ALLO‑316, recorded as a liability; related interest expense was $0.8 million year-to-date.
Allogene Therapeutics reported continued operating losses while preserving a multi-quarter cash runway as it refocuses clinical priorities. The company recorded a net loss of $50.9 million for the quarter and $110.7 million year-to-date, driven by research and development and general and administrative expenses, although total operating expenses declined versus prior-year periods. Cash, cash equivalents and investments totaled $302.6 million as of June 30, 2025, and management expects funding into the second half of 2027. The company completed a ~28% workforce reduction, recording related severance and impairment charges, and recognized impairment on a to-be-sublet leased facility and certain equipment.
Clinical updates include RMAT designation and positive signal durability for ALLO-316, IND clearance and trial initiation for ALLO-329 (RESOLUTION), and a consequential change in the ALPHA3 trial lymphodepletion approach: the FCA arm was closed after a Grade 5 adverse event attributed to ALLO-647 and standard fludarabine/cyclophosphamide (FC) was selected as the lymphodepletion regimen. The company received $9.2 million under an amended CIRM award recorded as a liability.